ADMA Biologics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Adam S. Grossman
- Full Time Employees
- 644
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 465 State Route 17 Ramsey NJ United States of America 07446
- IPO Date
- Oct 17, 2013
- CIK
- 0001368514
- Website
- admabiologics.com
- Similar Companies
- Business
- ADMA Biologics, Inc. ADMA Biologics, Inc. (ADMA) operates as an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for treating immunodeficient patients at risk for infection and others vulnerable to certain infectious diseases; its core products include three FDA-approved immune globulin therapies—ASCENIV™ (Immune Globulin Intravenous, Human – slra 10% liquid) and BIVIGAM® (Immune Globulin Intravenous, Human) for primary humoral immunodeficiency, and NABI-HB® (Hepatitis B Immune Globulin, Human) for enhanced immunity against hepatitis B virus—supported by a vertically integrated supply chain encompassing plasma collection via approximately 10 FDA-licensed ADMA BioCenters, fractionation and purification at its cGMP-compliant Boca Raton, Florida facility with up to 600,000 liters annual capacity, and contract development and manufacturing organization services. Founded in 2004 and headquartered in Ramsey, New Jersey, the company maintains U.S.-based operations focused on the immunology and infectious disease segments, targeting physicians, hospitals, infusion centers, and specialty pharmacies with its therapies derived from human plasma rich in neutralizing antibodies via proprietary microneutralization assays. Recent developments include FDA lot release authorization in 2025 for yield-enhanced commercial batches of its immune globulins to drive gross margin expansion starting in the fourth quarter, record ASCENIV demand with statistically significant real-world reductions in infection rates for primary immunodeficiency patients, advancing payer negotiations for broader 2026 reimbursement coverage, submission of a CNPV voucher application to bolster its SG-001 pipeline program, ongoing share repurchases funded organically, and a J.P. Morgan-led debt refinancing that strengthened its balance sheet with an undrawn $225 million revolver amid third-quarter 2025 revenue of $134.2 million.
Company News
Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
Bank of America Corp DE Raises Holdings in ADMA Biologics Inc $ADMA
Can Asceniv Help ADMA Stock Combat IG Market Challenges?
ADMA Biologics: The Earnings Reset Still Leaves More Upside
Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (ADMA)
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
ADMA Biologics, Inc. Deadline: ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law